Study of the regimen-specific HIV-1 genotypic susceptibility score after treatment failure

Authors: Beheydt G, Camacho R, Carvalho AP, Diogo I, Grossman Z, Ram D, Rudich H, Van Laethem K, Vandamme AM, Zazzi M
Journal: Antiviral Therapy
Link: https://apps.webofknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=3&SID=Z1yZbyGlNxI3xGo9eDj&page=1&doc=1

Expected HIV-1 etravirine resistance after treatment failure with efavirenz and/or nevirapine

Authors: Beheydt G, Camacho R, Carvalho AP, Grossman Z, Levy I, Ram D, Rudich H, Van Laethem K, Vandamme AM, Vercauteren J
Journal: Antiviral Therapy
Link: https://apps.webofknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=2&SID=Z1yZbyGlNxI3xGo9eDj&page=1&doc=1

Baseline susceptibility of primary HIV-2 to entry inhibitors.

Authors: Antunes F, Barroso H, Bártolo I, Borrego P, Caixas U, Calado R, Cavaco-Silva P, Doroana M, Maltez F, Marcelino JM, Rocha C, Taveira N
Journal: Antiviral Therapy
Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Baseline+susceptibility+of+primary+HIV-2+to+entry+inhibitors

BACKGROUND:
The baseline susceptibility of primary HIV-2 to maraviroc (MVC) and other entry inhibitors is currently unknown.
Read More

Development of a cross-European virtual sample repository and HIV resistance database.

Authors: Beheydt G, Fanti I, Imbrechts S, Incardona F, Kjaer J, Kristensen DK, Rickenbach M, Vandamme AM
Journal: Antiviral Therapy
Link: https://apps.webofknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=39&SID=2CbhBUDoSw8ZkFBEQLW&page=1&doc=1